VKTX: Unusual Options Flow & a Breakthrough Weight-Loss Drug

If you haven`t bought CKTX before the recent rally:

Now you need to know that Viking Therapeutics (VKTX) is a speculative biotech stock in the GLP-1/GIP agonist space, aiming to challenge market leaders like Eli Lilly and Novo Nordisk. Recently, I noticed unusual options flow — specifically, Jan 16, 2026 $60 strike calls

Key Bullish Points
1) Riding the Obesity Drug Boom
VK2735 is Viking’s dual agonist candidate showing promising early weight-loss efficacy, with potential overlap benefits in NASH (liver disease). The obesity treatment space is expected to exceed $100B by 2030—huge upside if their trials continue positively.

2) Options Flow Tells a Story
Those Jan 2026 $60 calls caught my attention precisely because the stock currently trades in the mid-$60s. These aren’t cheap lottery plays—they’re strategically timed wrt trial readouts, partnerships, or acquisition interest. Essentially, someone anticipates meaningful upside in the near future.

3) Descending Wedge — Chart Looks Bullish
VKTX peaked near $100, then pulled back into a well-defined descending wedge. If it breaks out above $70–$72 with volume, that could kick off a classic reversal trade.

Smart Money Options Flow — Near-Term Bet:
Recently, I spotted unusual open interest in $60 strike calls expiring Jan 16, 2026 — that’s only about 7 months away.
This means someone is positioning for a big upside move relatively soon, likely betting on positive Phase 2b/3 data, a partnership deal, or even buyout chatter within the next few quarters.

Short-dated, out-of-the-money call flow like this often hints at near-term news — not just a long-dated hedge.